These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 37965687)
1. Aberrant expression of GATA3 in metastatic adenocarcinoma of the prostate: an important pitfall. Lobo J; Tenace NP; Cañete-Portillo S; Carneiro I; Henrique R; Lucianò R; Harik LR; Magi-Galluzzi C Histopathology; 2024 Feb; 84(3):507-514. PubMed ID: 37965687 [TBL] [Abstract][Full Text] [Related]
2. Aberrant GATA3 Staining in Prostatic Adenocarcinoma: A Potential Diagnostic Pitfall. McDonald TM; Epstein JI Am J Surg Pathol; 2021 Mar; 45(3):341-346. PubMed ID: 32769430 [TBL] [Abstract][Full Text] [Related]
3. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung. Chang A; Amin A; Gabrielson E; Illei P; Roden RB; Sharma R; Epstein JI Am J Surg Pathol; 2012 Oct; 36(10):1472-6. PubMed ID: 22982890 [TBL] [Abstract][Full Text] [Related]
4. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. Epstein JI; Egevad L; Humphrey PA; Montironi R; Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122 [TBL] [Abstract][Full Text] [Related]
5. Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases. Nguyen NJ; Sherman C; van der Kwast TH; Downes MR Pathol Res Pract; 2024 Feb; 254():155105. PubMed ID: 38218041 [TBL] [Abstract][Full Text] [Related]
6. NKX3.1 as a marker of prostatic origin in metastatic tumors. Gurel B; Ali TZ; Montgomery EA; Begum S; Hicks J; Goggins M; Eberhart CG; Clark DP; Bieberich CJ; Epstein JI; De Marzo AM Am J Surg Pathol; 2010 Aug; 34(8):1097-105. PubMed ID: 20588175 [TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550 [TBL] [Abstract][Full Text] [Related]
8. Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: a diagnostic pitfall. Gordetsky J; Epstein JI Am J Surg Pathol; 2014 Jul; 38(7):941-5. PubMed ID: 24503758 [TBL] [Abstract][Full Text] [Related]
9. TRPS1 expression in primary and metastatic prostatic adenocarcinoma, muscle invasive bladder urothelial carcinoma, and breast carcinoma: Is TRPS1 truly specific and sensitive for a breast primary? Bachert SE; Di J; Zhang S; Short HE; Piecoro DW; McDonald RJ; Myint ZW; Hensley PJ; Allison DB Hum Pathol; 2024 Jan; 143():42-49. PubMed ID: 38052269 [TBL] [Abstract][Full Text] [Related]
10. GATA3 immunohistochemical expression in invasive urothelial carcinoma. Mohammed KH; Siddiqui MT; Cohen C Urol Oncol; 2016 Oct; 34(10):432.e9-432.e13. PubMed ID: 27241168 [TBL] [Abstract][Full Text] [Related]
11. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449 [TBL] [Abstract][Full Text] [Related]
12. Integrated immunohistochemical and molecular analysis improves diagnosis of high-grade carcinoma in the urinary bladder of patients with prior radiation therapy for prostate cancer. Chan E; Garg K; Stohr BA Mod Pathol; 2020 Sep; 33(9):1802-1810. PubMed ID: 32313185 [TBL] [Abstract][Full Text] [Related]
13. GATA3 expression in paragangliomas: a pitfall potentially leading to misdiagnosis of urothelial carcinoma. So JS; Epstein JI Mod Pathol; 2013 Oct; 26(10):1365-70. PubMed ID: 23599157 [TBL] [Abstract][Full Text] [Related]
14. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Genega EM; Hutchinson B; Reuter VE; Gaudin PB Mod Pathol; 2000 Nov; 13(11):1186-91. PubMed ID: 11106075 [TBL] [Abstract][Full Text] [Related]
15. [Metastatic lymph node collision of a prostatic adenocarcinoma and an urothelial carcinoma and review of the literature]. Junca A; Frouin E; Irani J; Fromont G; Levillain P Ann Pathol; 2015 Dec; 35(6):496-501. PubMed ID: 26597142 [TBL] [Abstract][Full Text] [Related]
16. Diagnostic utility of GATA3 immunohistochemical expression in urothelial carcinoma. Agarwal H; Babu S; Rana C; Kumar M; Singhai A; Shankhwar SN; Singh V; Sinha RJ Indian J Pathol Microbiol; 2019; 62(2):244-250. PubMed ID: 30971548 [TBL] [Abstract][Full Text] [Related]
17. Is GATA3 expression maintained in regional metastases?: a study of paired primary and metastatic urothelial carcinomas. Zhao L; Antic T; Witten D; Paner GP; Taxy JB; Husain A; Gwin K; Mirza MK; Lingen MW; Tretiakova MS Am J Surg Pathol; 2013 Dec; 37(12):1876-81. PubMed ID: 24121175 [TBL] [Abstract][Full Text] [Related]
18. A comprehensive analysis of GATA3 expression in carcinomas of various origins with emphasis on lung carcinomas. Bota EC; Koumoundourou D; Ravazoula P; Zolota V; Psachoulia C; Kardari M; Karampitsakos T; Tzouvelekis A; Tzelepi V; Sampsonas F Monaldi Arch Chest Dis; 2023 Aug; 94(2):. PubMed ID: 37667882 [TBL] [Abstract][Full Text] [Related]
19. Utility of uroplakin II expression as a marker of urothelial carcinoma. Tian W; Guner G; Miyamoto H; Cimino-Mathews A; Gonzalez-Roibon N; Argani P; Li X; Sharma R; Subhawong AP; Rezaei K; Bivalacqua TJ; Epstein JI; Bishop JA; Netto GJ Hum Pathol; 2015 Jan; 46(1):58-64. PubMed ID: 25449628 [TBL] [Abstract][Full Text] [Related]